Cambridge, UK, 14 March 2019. The o2h Therapeutics Fund & AI (“The Fund”), an early stage S/EIS fund investing in biotech therapeutic and related AI opportunities, has made its first investment, backing DeepMatter Group Plc (“DeepMatter”), a big data company which is at the forefront of the digitization of chemistry.
DeepMatter Plc is based in Glasgow and is quoted on the Alternative Investment Market (AIM). The group has developed DigitalGlasswareTM, an artificial intelligence-enabled cloud-based software and hardware platform allowing chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. This enables chemists to work together effectively, sharing the details of their experiments from anywhere and in real time, to help avoid work being needlessly duplicated, and ultimately so new discoveries may be made faster.
Sunil Shah, CEO of o2h Ventures, who manages the fund alongside Prashant Shah, Managing Partner, said: “This is a really exciting moment for us; this is the first of five exciting deals we hope to close in the next two months covering our unique scientific strengths in therapeutics and where AI meets therapeutics. This is the first Fund in the world specialising in early-stage therapeutics and enabling AI technology.”
“I have known Mark Warne, the CEO, for over a decade; he is an entrepreneur that we are delighted to be backing. DeepMatter is seeking to disrupt the established chemistry sector and provide intelligent information to pharmaceutical chemistry companies, which is a multibillion-dollar industry. We have evaluated many AI companies in this space and believe that DeepMatter is in a strong position to collect the volume of training data required for autonomous machine learning.”
Mark Warne, CEO of DeepMatter, said: “We are delighted that o2h Ventures has recognised that AI has a huge role to play in the way that pharmaceutics chemistry is carried and the confidence that they have in our platform. The investment allows us to continue cementing DeepMatter’s long-term development strategy, providing funding that ensures we remain at the forefront of the digitization of chemistry.”
About o2h Ventures:
o2h Ventures Limited has launched the o2h Therapeutics fund which is the first S/EIS fund in the UK solely focused on early-stage biotech therapeutics and related AI opportunities. The geographic scope shall be UK wide including Oxford and London but will target the growing Cambridge biotech cluster. The fund is structured to be S/EIS compliant providing tax breaks for UK taxpayers.
The biotech sector is one of the leading sectors in the UK economy. The large pharma companies now rely on the small innovative biotechs for new ideas in disease areas such as cancer, genomics, anti-ageing and neurosciences amongst others which has led to higher potential exit valuations. The fund will widen the community of investors that will help expand early-stage research in the UK.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h operate from their proprietary 2.7 acres o2h SciTech Park where they have developing a unique model for incubating small life science companies.
More information is available here: https://www.o2hventures.com/
Marketing and PR
DeepMatter Group Plc is a big data and analysis company which has built a platform – DigitalGlassware™, focused on enabling reproducibility in chemistry. It continues to develop this software to deliver applications resulting in new optimised chemicals, materials and formulations in such commercially significant areas as pharmaceutical research, fine chemicals, scientific publications and teaching. DeepMatter is at the forefront of the digitization of chemistry, which will ultimately see the enabling of an autonomous synthesis engine, the Chemputer™.
More information is available here: http://www.deepmattergroup.com